$CYBN Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder https://www.businesswire.com/news/home/20240123732289/en/Cybin-Announces-FDA-Clearance-to-Initiate-a-Phase-2a-Study-of-CYB004-in-Generalized-Anxiety-Disorder